Roche's $2.3 Billion Bet on a Muscle That Won't Quit
Roche just dropped $2.3 billion on a weight-loss drug that doesn't work like any other obesity treatment on the market. Instead of suppressing appetite, HM17321 targets a completely different pathway, one that burns fat while building muscle.
The Obesity Drug Race Just Got a Plot Twist
Everyone in the weight-loss drug game is chasing the same thing: make people lose more weight, faster. Novo Nordisk and Eli Lilly have been locked in a two-horse race, each throwing bigger and better GLP-1 drugs at the problem. Then Roche walks in and says, "What if the real question isn't how much weight you lose, but what kind of weight you lose?"
That's the bet behind Roche's new $2.3 billion deal with South Korea's Hanmi Pharmaceutical, announced this week. And it might be the most interesting strategic move in obesity pharma this year.
What Roche Is Actually Buying
The deal gives Roche's Genentech unit global rights (outside South Korea) to a drug called HM17321. The upfront check: $190 million. The rest of the $2.3 billion comes from development, regulatory, and commercial milestones, plus tiered royalties on future sales.
But the dollar signs aren't what makes this deal fascinating. It's the science.
HM17321 is not another GLP-1 drug. It's not even in the same family. It's a long-acting urocortin-2 analog, a first-in-class molecule that targets something called the CRF2 receptor. In plain English: while most obesity drugs work by suppressing appetite through your gut hormones, this one takes a completely different route. Think of it like trying to get across town. Everyone else is stuck on the highway; Roche just found a back road.
The pitch is compelling. In preclinical studies (animal models of obesity), HM17321 reduced fat mass while simultaneously increasing lean muscle mass. The drug appears to stimulate muscle cell growth through a pathway called mTOR, which is basically the body's "build muscle" signal. It also promotes fat breakdown in fat cells.
If you've ever heard someone complain that weight-loss drugs make people look "deflated" because they lose muscle along with fat, this is the drug designed to solve that problem.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why Roche Needs a Different Playbook
Roche is late to the obesity party, and it knows it. Novo Nordisk has Wegovy (semaglutide) and a massive installed base of patients. Eli Lilly has Zepbound (tirzepatide), the now-approved oral pill orforglipron (marketed as Foundayo), and a triple-agonist (retatrutide) that could push weight loss even further.
Roche has been playing catch-up. It acquired Carmot Therapeutics in late 2023 to get CT-388, a GLP-1/GIP dual agonist now in late-stage development. Last year, it partnered with Zealand Pharma on petrelintide, an amylin analog meant to complement its GLP-1 program. Multiple analysts have described Roche as a late entrant that needs differentiation, not just another me-too injectable.
So rather than trying to out-Lilly Lilly on sheer weight-loss numbers, Roche is building a combo strategy. CT-388 handles the traditional appetite-suppression angle. Petrelintide adds amylin biology. And now HM17321 brings the body-composition angle: lose the fat, keep the muscle.
It's like assembling a basketball team. You don't need five point guards. You need players who do different things well.
Hanmi: The Licensing Machine You Probably Haven't Heard Of
Hanmi Pharmaceutical might not be a household name, but big pharma keeps knocking on its door. The Roche deal isn't even Hanmi's biggest licensing event this year.
Earlier in 2026, Eli Lilly paid Hanmi $75 million upfront (up to $1.185 billion total) for sonefpeglutide, a separate obesity candidate. Before that, Hanmi had deals with Merck (up to $860 million for a GLP-1/glucagon dual agonist) and Janssen (up to $915 million for an obesity and diabetes treatment).
The pattern is clear: Hanmi develops novel metabolic drugs internally, then licenses them to the biggest names in pharma. The company reportedly spends about 14% to 15% of annual revenue on R&D, and its obesity pipeline now includes at least three distinct assets targeting different biological pathways.
Multiple Korean securities analysts raised their price targets for Hanmi after the Roche announcement. KB Securities bumped its target to 650,000 won, while Mirae Asset went to 730,000 won, arguing that Roche likely licensed HM17321 specifically to build a more differentiated obesity franchise.
The Muscle Problem Nobody Wants to Talk About
Weight-loss drugs have a dirty little secret: they don't just burn fat. Patients on GLP-1 drugs can lose significant amounts of lean muscle mass along with their fat. For older patients or anyone trying to maintain metabolic health long-term, that's a real concern.
This is why "body composition" is becoming the new battleground. It's not enough to make the number on the scale go down. The quality of weight loss matters: ideally, you want patients losing fat and keeping (or building) muscle.
HM17321 is still early. The drug is in Phase 1 testing, which Hanmi is completing before handing off to Genentech for Phase 2 and beyond. That means we're years away from knowing whether the preclinical promise translates into real results in humans. Plenty of drugs look great in mice and flop in people.
But the strategic logic is sound. If Roche can prove that its combination approach delivers not just weight loss but better weight loss, it wouldn't need to beat Lilly and Novo on raw percentage points. It could carve out an entirely different positioning.
The Bigger Picture
The obesity drug market in 2026 is evolving fast. The Novo-Lilly duopoly still dominates, but competition is fragmenting across several dimensions: oral versus injectable delivery, single-target versus multi-agonist approaches, and now, incretin-based versus non-incretin mechanisms.
Roche's Hanmi deal is a clear signal that the company sees the future of obesity treatment as combination therapy, not monotherapy. One drug to suppress appetite. Another to boost metabolic activity. A third to protect muscle. It's the cocktail approach that transformed HIV treatment decades ago, now applied to metabolic disease.
Whether it works is another question entirely. HM17321 is a Phase 1 asset with only animal data behind it. The $190 million upfront payment reflects real conviction, but the remaining $2.1 billion in milestones is contingent on clinical success that's far from guaranteed.
Still, the signal matters. Roche isn't trying to win the same race as everyone else. It's trying to change what the finish line looks like. And in a market projected to be worth tens of billions of dollars annually, there's room for more than one definition of success.
The obesity arms race just got a lot more interesting.
Clinical & Regulatory4 min read
Lutathera Just Got Its First Copycat. Radioligand Therapy Will Never Be the Same.
The FDA just approved the first-ever generic radioligand drug, a copycat of Novartis' blockbuster Lutathera. It's a regulatory first that could crack open pricing and competition in one of oncology's most complex (and expensive) drug categories.
